Skip to Content
Merck
  • Synthesis, vasorelaxant activity and antihypertensive effect of benzo[d]imidazole derivatives.

Synthesis, vasorelaxant activity and antihypertensive effect of benzo[d]imidazole derivatives.

Bioorganic & medicinal chemistry (2010-05-11)
Gabriel Navarrete-Vázquez, Sergio Hidalgo-Figueroa, Mariana Torres-Piedra, Jorge Vergara-Galicia, Julio Cesar Rivera-Leyva, Samuel Estrada-Soto, Ismael León-Rivera, Berenice Aguilar-Guardarrama, Yolanda Rios-Gómez, Rafael Villalobos-Molina, Maximiliano Ibarra-Barajas
ABSTRACT

A series of 1H-benzo[d]imidazole analogues of Pimobendan, substituted at position 5 with either -CF(3) or -NO(2), were synthesized using a short synthetic route. All the nitro derivatives were potent, and exhibited a concentration- and partial endothelium-dependent vasorelaxant effects, with EC(50)s <5microM. 2-Methoxy-4-[5-nitro-1H-benzo[d]imidazol-2-yl]phenol (compound 13) was the most potent derivative of the series, showing an EC(50) value of 1.81microM and E(max) of 91.7% for ex vivo relaxant response in intact aortic rings, resulting in a 2.5-fold higher activity compared to Pimobendan. The closely related 5-CF(3) analogue (compound 8), was 19 times less potent than 13. The antihypertensive activity of compound 13 was evaluated at doses of 25, 50 and 100mgkg(-1), using spontaneously hypertensive rats (SHR), showing a statistically significant dose-dependent effect.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Carbamoylcholine chloride, ≥98% (titration), crystalline
Pimobendan for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Captopril, ≥98% (HPLC), powder
Sigma-Aldrich
Nitrendipine, >95%, powder
Sigma-Aldrich
Captopril, meets USP testing specifications